🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This week at EMBO #Cilia2022 in Cologne, our own Mirko Hennig, presented important preclinical data that showed our investigational inhaled DNAI1 mRNA treatment for #PCD has low immune reactivity, rescues ciliary function & results in long-lasting functional recovery.

#CysticFibrosis (CF) can make it very difficult to breathe. This #HealthyLungMonth, we’re raising awareness about this disease and the way in which it affects the lungs. Learn more about CF and our approach to a CFTR mRNA therapy at recodetx.com/pipeline/.

#PrimaryCiliaryDyskinesia, or #PCD, is challenging to diagnose leading to both missed diagnosis and misdiagnosis. Although there is no treatment for PCD, an early diagnosis can help protect and delay damage to the lungs. Source: nhlbi.nih.gov/health/primary…. #PCDAwarenessMonth

Will we see you at #PODD2022 in Boston next week? On Monday, our director of BD Ariel Kantor will talk about how our novel SORT LNP platform is overcoming the limitations of conventional LNPs to enable superior delivery of #RNA and next-gen gene correction therapeutics

This #LungHealthDay, we recognize the importance of #LungHealth and show support to those living with a rare lung condition. At Recode, we aim to improve the lives of these patients by developing genetic medicines with superior delivery. Learn more at recodetx.com/pipeline/

We’re very proud to have been nominated for the 2022 #PrixGalien award for “Best Startup in the Pharmaceutical or Biotechnology Industry.” Thank you The Galien Foundation for this honor and congratulations to all of this year’s winners and nominees for your work to improve human health!

We’re excited to attend #NACFC2022 this year with other members of the #CysticFibrosis community. Please visit us at booth #1020 to learn more about our investigational therapy for CF patients who have nonsense mutations & do not respond to currently approved CFTR modulators.

This month, we’ll be participating in the Credit Suisse and Stifel Healthcare Conferences. We’re looking forward to sharing more about our novel #genetic #medicines delivery platform and pipeline of disease-modifying #mRNA & gene correction therapeutics. recodetx.com/recode-therape…

We want to say thank you to everyone who participated in the #NACFC2022 conference this year. We’re truly inspired by the passionate people we met who are carrying forward research to treat the thousands of people living with #CysticFibrosis.

On this week’s episode of The Long Run podcast, our CEO Shehnaaz suliman had the opportunity to speak with Luke Timmerman about her #leadership journey, our strategy and vision, and how we're improving the delivery of #geneticmedicine. Take a listen! bit.ly/3NLHmtj

We’re at the @mRNAConference this week. Come join our session at 3:10pm ET where David Lockhart, our President and CSO, will be talking about our SORT LNP-formulated mRNA for the treatment of #PrimaryCiliaryDyskinesia.

Better delivery platforms can unleash the true potential of genetic medicines. These must deliver drugs beyond the liver – to the lungs, spleen, and beyond. Learn how we are powering the next wave of genetic medicines through superior delivery: recodetx.com